

ATS 2022 International Conference Planner Disclosure Summary

May 13 – May 18, 2022

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, and those of the ATS Policy on Management of Conflict of Interest in Official ATS Documents, Projects and Conferences, ATS Policy Governing Relationships Between the Tobacco Industry, ATS Members, and Non-Members Who Participate in ATS Activities, and ATS Policy on Professionalism and Ethical Conduct, chairs, moderators, presenters and official planners of the International Conference are required to disclose to ATS any potential conflicts of interest (COI) held by them relevant to their presentation(s) or conference role, including all professional or other financial involvement with tobacco or e-cigarette entities, all relevant financial relationships with ineligible companies, and all other relationships that could be perceived as influencing their participation.

For the 2022 ATS International Conference, this disclosure information for all individuals in control of content was requested and received by ATS in advance of the Conference, reviewed by appropriate ATS reviewers, and session chairs and others in positions of authority were instructed to manage and mitigate identified faculty conflicts according to procedures overseen by the ATS Ethics and Conflict of Interest Committee.

The following members of the International Conference Committee have disclosed the following financial relationships with ineligible companies:

Name,

Relationship: Company

Matthew G. Drake, Advisory Committee - non-promotional: Astra Zeneca, GlaxoSmithKline, Merck

Foundation; Research Support: Cystic Fibrosis Foundation

Frits Franssen, Research Support: AstraZeneca; Speaker/Faculty - non-promotional: Boehringer Ingelheim; Advisory Committee - non-promotional: Chiesi; Consultant: GlaxoSmithKline; Advisory Committee - non-promotional: Novartis

Joyce S. Lee, Data Safety and Monitoring Board: Avalyn; Advisory Committee - non-promotional: Boehringer Ingelheim, Galapagos; Research Support: Boehringer Ingelheim, NIH; Consultant: Bonac, ElevenP15, United Therapeutics; Advisory Committee - non-promotional: Employment: Pulmonary Fibrosis Foundation; Data Safety and Monitoring Board: United Therapeutics

Jed A. Gorden, Advisory Committee - non-promotional: AstraZeneca, Daiichi Sankyo; Consultant: Noah Medical, Verathon

Valerie G. Press, Research Support: American Lung Association, NIH; Consultant: Humana, Vizient

Brian B. Graham, Research Support: NIH/NHLBI

Corey E. Ventetuolo, Consultant: Altavant Sciences; Research Support - Industry Initiated: Eiger; Research Support: United Therapeutics

Shannon H. Kasperbauer, Consultant: Insmad, AN2; Speaker/Faculty - non-promotional: Paratek

Benjamin T. Kopp, Research Support: Cystic Fibrosis Foundation, Generian

Jason C. Woods, Consultant: Vertex; Research Support: Vertex

Terri A. Laguna, Advisory Committee - non-promotional: NIH; Research Support: NIH; Advisory Committee - non-promotional: Cystic Fibrosis

All relevant financial relationships for these individuals have been reviewed and mitigated.

The following members of the International Conference Committee have disclosed no financial relationships with ineligible companies:

Felicity Blackstock
Jessica Bon
Debra M. Boyer
Laura E. Crotty Alexander
Sharron J. Crowder
Annette M. Esper
Chadi A. Hage
Andrew J. Halayko
Blanca E. Himes

Erin K. Kross
Lea Ann Matura
Mary B. Rice
Neomi A. Shah
Christopher M. Waters
Elizabeth Wilcox
Rachel L. Zemans
Andrey Zinchuk

The following members of the Education Committee have disclosed the following financial relationships with ineligible companies:

Name

Relationship: Company

Gerene S. Bauldoff - Royalties, licensing fees, or other sales proceeds: Pearson Education

Tristan J. Huie - Research Support - industry initiated: Boehringer Ingelheim, Roche/Genentech, Pulmonary Fibrosis Foundation

Shirin Shafazand - Consultant: AstraZeneca

Krishna M. Sundar - Ownership or investment interests (includes stock): Hypnoscore LLC; Advisory Committee: Merck Inc.; Research Support: Phillips Respironics Inc.

Laren Tan - Consultant: AstraZeneca, Boston Scientific; Speaker/Faculty – Promotional: Boehringer Ingelheim, Sanofi Regeneron

Tisha S. Wang – Consultant: IQVIA, Partner Therapeutics; Advisory Committee: Kinevant

All of the relevant financial relationships for these individuals have been mitigated

The following members of the International Conference Committee have disclosed no financial relationships with ineligible companies:

Shozab Ahmed
Erin R. Camac
Joselyn L. Cho
Basak Coruh
Jane C. Deng
Javier Diaz-Mendoza
Katherine A. Dudley
Fei Jamie Dy
Rania Esteitie

Garth W. Garrison
Jane E. Gross
Robin L. Gross
Margaret M. Hayes
Diana Kelm
Edward Kilb
Carmen Leon-Astudillo
Melissa Lipford
James D. Londino

Michael McCown
Jakob I. McSparron
Scott S. Oh
Caroline Okorie
Majid Shafiq
Maria Elena Vega Sanchez
Michelle R. Zeidler

The following members of the ATS Education Department Staff have disclosed no financial relationships with ineligible companies: Suzette Machado, MPA, CHCP

The following members of the ATS staff responsible for conflict of interest management disclosed the following financial relationships with ineligible companies:

Shane McDermott, Senior Director, Ethics and Professionalism

Investment interests includes stock held within pension funds independently managed by Fidelity Investments and Nationwide.

The following members of the ATS staff responsible for conflict of interest management have disclosed no financial relationships with ineligible companies:

John Harmon, Associate Director, COI and Documents